Security key
690469101
Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID)
CUSIP: 690469101
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 105,065,946
- Total 13F value
- $233,184,546
- Share change
- +40,375,633
- Put/Call ratio
- 163%
- SEC-reported price per share
- $2.22
- Number of holders
- 103
- Value change
- +$91,068,941
- Number of buys
- 58
- Number of sells
- 29
- Shares outstanding
- 146,457,154
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q1 2026
Institutions
103
Top holders
10
OVID full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 690469101
Recent filing periods:
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
Disclosed value leader
Sirenia Capital Managemen...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
13D/G row: TAKEDA PHARMACEUTICAL CO LTD
Showing 1-6 of 15 holder rows.
Quick read
TAKEDA PHARMACEUTICAL CO LTD leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
TAKEDA PHARMACEUTICAL CO LTD
12%
JANUS HENDERSON GROUP PLC
10%
Sirenia Capital Management LP
9.9%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Affinity Asset Advisors, LLC
9.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD |
13D/G
3/4/5
Takeda Pharmaceutical Company Limited · 10%+ Owner
|
12%
|
$11,680,055
8,781,996 shares
|
$0 | 08 Dec 2025 |
| JANUS HENDERSON GROUP PLC |
13D/G
|
10%
|
$9,461,772
7,114,114 shares
|
$0 | 28 Nov 2025 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$51,930,239
18,031,333 shares
|
$0 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
9.9%
|
$19,889,602
13,259,735 shares
|
$0 | 11 Dec 2025 |
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
9.1%
|
$45,030,194
15,635,484 shares
|
+$10,040,596 | 31 Mar 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
13F
Company
|
7.3%
|
$36,787,902
12,773,577 shares
|
$0 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
103
Shares
105,065,946
Rows available
103
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
83
Q1 2026 holders
103
Holder diff
20
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend